Perceptive Advisors

Public Equity Report: French biotech to fund MASH study with €348M lifeline; bispecifics developer raises $250; DMD cardiomyopathy play prices follow-on

Biotech engineers its antibody-drug conjugates to unbind their target upon internalization, recycling it back to the cell surface to recruit more ADCs

Plus: MeiraGTx, scPharmaceuticals each raise $50M

Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers

Plus: PIPEs help Celcuity, Cargo advance clinical programs

Plus: Adcendo’s series A is again Denmark’s largest; VCs and foundations back Lucy

Plus: IPO updates from Sunho, Rapport; Bicycle’s massive PIPE; Dyne’s opportunistic follow-on; and more

Plus: Progentos’ launch; series B rounds for AltruBio, Pheon and Grey Wolf; a series A for Vienna-based Ygion; and more

Plus: OnKure goes public via reverse merger, Monte Rosa and Allogene each raise $100M+, and Incyte’s $2B buyback

Plus Eliem, Century raise private placements as they make acquisitions; Nurix’s AACR readout precedes follow-on; Skye uplists